eNeura, Inc., a privately held medical technology company, announced that it has obtained an expanded CE Marking in Europe extending the label for its SpringTMS device to include migraine prevention. The label extension adds to the existing SpringTMS CE Marking for acute treatment of migraine and UK National Institute for Health and Care Excellence (NICE) guidance recommending single-pulse Transcranial Magnetic Stimulation (sTMS) for acute and preventative treatment of migraine.